SCHEMBL5563236

SCHEMBL5563236

CC(=O)NC(C=O)Cc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 5/20 0.58
CTRB1 P17538 4/20 0.57
CTSB P07858 3/20 0.57
ACE P12821 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2266848 1.00 CAPN1 (0.58) CAPN1CTRB1CTSBACE
SCHEMBL2269431 1.00 CAPN1 (0.58) CAPN1CTRB1CTSBACE
SCHEMBL12290446 0.87 CAPN1 (0.56) CAPN1CTSBACE
SCHEMBL3292711 0.86 CAPN1 (0.61) CAPN1CTSBACE
SCHEMBL17865652 0.86 CAPN1 (0.61) CAPN1CTSBACE
SCHEMBL2369340 0.86 CAPN1 (0.61) CAPN1CTSBACE
SCHEMBL2270660 0.85 ACACB (0.54) CAPN1CTRB1CTSB
SCHEMBL2268108 0.85 ESR1 (0.47) CAPN1CTSB
SCHEMBL7796543 0.85 CTRB1 (0.59) CTRB1
SCHEMBL14542450 0.85 CAPN1 (0.43) CAPN1CTRB1CTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227425-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION STUDIENGESELLSCHAFT KOHLE MBH (DE) 2023-07-20 US disclosed
WO-2021110076-A1 OXAMIDE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF IN MEDICINE 深圳信立泰药业股份有限公司 2021-06-10 WO disclosed
EP-1568701-B1 TRANSITION METAL COMPLEX HAVING DIPHOSPHINE COMPLEX AS LIGAND TAKEDA PHARMACEUTICAL (JP) 2010-01-20 EP disclosed
WO-2009070631-A2 ETHOID COMPOUNDS FOR USE AS FOOD ADDITIVES UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2009-06-04 WO disclosed
WO-2008117054-A2 CHIRAL DIPHOSPHINES, METHODS FOR THEIR PREPARATION, TRANSITION METAL COMPLEXES COMPRISING THEM AND USE IN CHIRAL SYNTHESIS CELTIC CATALYSTS LIMITED (IE) 2008-10-02 WO disclosed
US-7183443-B2 Process for the preparation of enantiomerically enriched compounds DSM IP ASSETS B.V. (NL) 2007-02-27 US disclosed
CN-1726044-A Compositions and methods for enhancing mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity NASTECH PHARM CO (US) 2006-01-25 CN disclosed
US-20050215822-A1 Process for the preparation of enantiomerically enriched compounds DSM IP ASSETS B.V. (NL) 2005-09-29 US disclosed
EP-1492760-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED COMPOUNDS DSM IP Assets B.V. (NL) 2005-01-05 EP disclosed
WO-2003087033-A1 PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED COMPOUNDS DSM IP ASSETS B.V. (NL) 2003-10-23 WO disclosed
CN-1021910-C LANKACIDIN DERIVATIVES AND PRODUCTION THEREOF TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1993-08-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215822-A1 Process for the preparation of enantiomerically enriched compounds ADH1C, ADH1A, ADH5 CAPN1 3061/4885CTRB1 2980/4885CTSB 3846/4885
US-20230227425-A1 REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION CFH, DOHH, CTSH CAPN1 1871/4885CTRB1 893/4885CTSB 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.